An ongoing, randomized phase II study of Nivolumab plus Ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST)

Ahrens M, Escudier B, Haanen JBAG, Boleti E, Goupil GM, Grimm MO, Negrier S, Barthelemy P, Gravis G, Ivany P, Bedke J, Castellano D, Panic A, Mellado B, Maroto JP, Roten S, Zschaebitz S, Deckbar D, Hartmann A, Bergmann L (2021)


Publication Type: Conference contribution

Publication year: 2021

Journal

Publisher: KARGER

City/Town: BASEL

Pages Range: 74-75

Conference Proceedings Title: ONCOLOGY RESEARCH AND TREATMENT

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Ahrens, M., Escudier, B., Haanen, J.B.A.G., Boleti, E., Goupil, G.M., Grimm, M.O.,... Bergmann, L. (2021). An ongoing, randomized phase II study of Nivolumab plus Ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST). In ONCOLOGY RESEARCH AND TREATMENT (pp. 74-75). BASEL: KARGER.

MLA:

Ahrens, M., et al. "An ongoing, randomized phase II study of Nivolumab plus Ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST)." Proceedings of the ONCOLOGY RESEARCH AND TREATMENT BASEL: KARGER, 2021. 74-75.

BibTeX: Download